Fig. 5
From: CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model
CRISPR/Cas9 editing of GPRC6A impairs osteocalcin-induced gene expression. Control and CRISPR/Cas9 edited PC-3 cells were treated with 100 ng/ml osteocalcin or vehicle for 24 h, gene expression was analyzed by qRT-PCR. c-Fos gene expression (a); cell migration markers, MMP9 (b), VEGF (c) and BMP3 gene expression (d); prostate cancer progression markers, PSA (e), RUNX2 (f), and OCN gene (g) expression. Testosterone biosynthesis pathway enzymes, HSD17B11 (h) HSD3B1 (i), and AKR1C3 gene expression (j). ** indicates a significant difference from control and stimulated groups at p < 0.01 (n = 6)